Adam Lynch Joins NorthStar Medical Radioisotopes Executive Team

NorthStar Medical Radioisotopes LLC has welcomed a new member to its management team.

Adam D. Lynch joins the company as vice president, corporate development and external affairs. He reports to NorthStar President and CEO Stephen Merrick.  

“NorthStar has established itself as a leader in the radiopharmaceutical sector by developing and delivering solutions for reliable medical radioisotope supply,” said Lynch. “I’m excited at the opportunity to be part of this team at a pivotal moment in its growth, and look forward to contributing my strategic corporate development and finance experience to expand access to medical radioisotopes produced in the United States that are critical for healthcare. Together, we can ensure that we meet the needs of health systems across the country and the many millions of patients who can benefit from NorthStar’s products.”

Before joining NorthStar, Lynch was an executive for Humboldt Park Health, which he led through the initial surge and secondary uptick in COVID-19 positive inpatients. Simultaneously, Lynch completed a $32.3 million financing and directed advocacy for what became $36.3 million in COVID-19 relief aid. Previously, he managed the divestiture of five business units for Northwestern Medicine and, as group vice president, supervised post-merger integration for the Illinois Health and Hospital Association.

Lynch has been an innovator in the healthcare industry. He launched the MetroChicago Health Information Exchange and was instrumental in developing a health insurance company. Earlier roles included serving as vice president at Principle Valuation, a specialty healthcare valuation and advisory firm and Citadel Group Limited, where he developed and invested more than $1.5 billion in medical real estate. Lynch has been recognized by the American College of Healthcare Executives (ACHE) with a Regent Award and is a Crain’s Chicago 40 under 40 honoree. He is a former Regional Executive of Healthcare Financial Management Association (HFMA) and past president of the First Illinois Chapter.

Lynch graduated from the University of Wisconsin, Milwaukee.

“Adam’s leadership and experience in driving successful corporate development outcomes position him as a key contributor to NorthStar’s continued growth as we expand awareness and availability of our domestically produced and environmentally sound medical radioisotope products with U.S. health systems,” said Merrick. “As a key member of our leadership team, Adam will initially focus on working with health systems and other key stakeholders to help them realize the benefits of using technetium-99m (Tc-99m) derived from domestically produced, non-uranium based molybdenum-99 (Mo-99). Tc-99m is the most widely used medical imaging radioisotope, used in 40,000 patient procedures daily. Access to reliable, sustainable and diversified Tc-99m supply is of paramount importance for U.S. healthcare, the economy and the environment. Adam’s strategic acumen and in-depth experience in healthcare, business and finance will help advance NorthStar in our next stage of corporate growth across the radiopharmaceutical industry, and we welcome him to the team.” 
 
NorthStar Medical Radioisotopes is a commercial-stage nuclear medicine company that manufactures and distributes diagnostic and therapeutic radiopharmaceuticals.